LeMaitre Vascular (LMAT) stock is experiencing a sharp pre-market plunge of 9% on Friday, following the company's fourth-quarter 2024 earnings report and disappointing first-quarter 2025 guidance released after the market close on Thursday.
The medical device maker reported Q4 2024 earnings per share (EPS) of $0.49, in line with analysts' estimates. However, the company's Q4 revenue of $55.7 million missed Wall Street's consensus estimate of $56 million. This revenue miss appears to be the primary driver behind the stock's steep decline in pre-market trading.
Adding to investor concerns, LeMaitre's Q1 2025 revenue guidance of $56.7-$58.7 million also fell short of analysts' expectations, further exacerbating the sell-off. While the company's Q1 EPS guidance range of $0.48-$0.53 was in line with estimates, the weak revenue outlook overshadowed this positive aspect, weighing heavily on the stock's performance.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。